Results 101 to 110 of about 52,382 (294)

Retrospective evaluation of palliative care consultation in critically ill adult and pediatric cancer subjects

Pediatric Investigation, EarlyView.
Children with cancer received more palliative care consultation before, but fewer during, critical illness compared with adults. This disparity suggests underuse of palliative care during pediatric critical care. ABSTRACT Importance Palliative care consultation is an essential component of comprehensive care for patients with cancer during critical ...
Conrad Krawiec, Neal Thomas
wiley   +1 more source

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Haematologica, 2012
Background Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation.
Jeffrey J. Pu, Rong Hu, Galina L. Mukhina, Hetty E. Carraway, Michael A. McDevitt, Robert A. Brodsky   +5 more
doaj   +1 more source

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease [PDF]

, 2017
Azacitidine (Aza) is first-line treatment for patients with high-risk myelodysplastic syndromes (MDS), although its precise mechanism of action is unknown. We performed the first study to globally evaluate the epigenetic effects of Aza on MDS bone marrow
Abdulkadir, Hani, Ben Azenkoud, Asmaa, Corddedu, Lina, De Paepe, Ayla, Einarsdottir, Elisabet, Ekwall, Karl, Grovdal, Michael, Hellstrom-Lindberg, Eva, Jansson, Monika, Karimi, Mohsen, Katayama, Shintaro, Kere, Juha, Krjutskov, Kaarel, Lehmann, Soren, Lennartsson, Andreas, Marabita, Francesco, Tobiasson, Magnus, Ungerstedt, Johanna   +17 more
core   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients

Haematologica, 2016
The clinical and histopathological distinctions between inherited versus acquired bone marrow failure and myelodysplastic syndromes are challenging.
Siobán B. Keel, Angela Scott, Marilyn Sanchez-Bonilla, Phoenix A. Ho, Suleyman Gulsuner, Colin C. Pritchard, Janis L. Abkowitz, Mary-Claire King, Tom Walsh, Akiko Shimamura   +9 more
doaj   +1 more source

The impact of delayed sample handling and type of anticoagulant on the interpretation of dysplastic signs detected by flow cytometry [PDF]

, 2018
L
Arber, Carter, Della Porta, Dransfield, Dransfield, Elghetany, Hart, Hodge, Jafari, Jones, Kern, Kárai, Latger-Cannard, Malcovati, Mathis, Nusbaum, Ogata, Porwit, Repo, Saxton, Sengeløv, Stenberg, Valent, van de Loosdrecht, Westers, Westers, Whyte, Wood, Youssef   +28 more
core   +2 more sources

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts [PDF]

, 2017
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
AM Zeidan, AO Soriano, BD Cheson, BD Cheson, CJ Clopper, D Merkel, DJ DeAngelo, E Raffoux, G Garcia-Manero, G Garcia-Manero, G Garcia-Manero, H Dombret, H Khan, J Babb, JP Issa, JP Issa, JP Laubach, L Maurillo, L Pleyer, M Kirschbaum, M Lubbert, Mikkael A. Sekeres, P Atadja, P Fenaux, P Fenaux, P Maslak, P Tan, PG Richardson, SD Gore, SD Nimer, T Prebet, TE Fandy, W Blum, W Fiskus, Y Ofran, YG Lee   +35 more
core   +2 more sources

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Haematologica, 2017
Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage.
Theresia M. Westers, Eline M.P. Cremers, Uta Oelschlaegel, Ulrika Johansson, Peter Bettelheim, Sergio Matarraz, Alberto Orfao, Bijan Moshaver, Lisa Eidenschink Brodersen, Michael R. Loken, Denise A. Wells, Dolores Subirá, Matthew Cullen, Jeroen G. te Marvelde, Vincent H.J. van der Velden, Frank W.M.B. Preijers, Sung-Chao Chu, Jean Feuillard, Estelle Guérin, Katherina Psarra, Anna Porwit, Leonie Saft, Robin Ireland, Timothy Milne, Marie C. Béné, Birgit I. Witte, Matteo G. Della Porta, Wolfgang Kern, Arjan A. van de Loosdrecht   +28 more
doaj   +1 more source

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

British Journal of Haematology, EarlyView.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis   +18 more
wiley   +1 more source